VCM
CORT icon

Voleon Capital Management’s Corcept Therapeutics CORT Stock Holding History

Voleon Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99M Sell
91,926
-170,297
-65% -$10.3M 0.15% 143
2026
Q1 		$10.6M Buy
+262,223
New +$9.81M 0.23% 101
2025
Q4 		– Sell
-2,815
Closed -$234K – 832
2025
Q3 		$234K Buy
+2,815
New +$204K 0.01% 790

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voleon Capital Management's CORT Position: Q2 2026 in Review

Voleon Capital Management reduced its Corcept Therapeutics (CORT) stake by 65% in Q2 2026, selling an estimated $10.3M and leaving 91,926 shares worth $7.99M. The position accounts for 0.15% of the portfolio, ranked #143.

Voleon Capital Management first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.6M in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Voleon Capital Management held 91,926 shares of Corcept Therapeutics worth $7.99M as of Q2 2026.
  • Voleon Capital Management sold 170,297 Corcept Therapeutics shares in Q2 2026, an estimated $10.3M.
  • Corcept Therapeutics made up 0.15% of Voleon Capital Management's portfolio in Q2 2026, its #143 holding.
  • Voleon Capital Management first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Voleon Capital Management's Corcept Therapeutics position peaked at $10.6M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.